or
forgot password

    • cancer clinical trials in mcallen, TX

    • Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
    South Texas Regional Cancer Centers - McAllen
    McAllen, Texas 78503
    Colorectal Cancer
    PhII ICb With/Without Erbitux in MBC Pts
    South Texas Cancer Center-McAllen
    McAllen, Texas 78503
    Metastatic Breast Cancer
    Adj TC + Herceptin Early Stage Breast Cancer
    South Texas Cancer Center-McAllen
    McAllen, Texas 78503
    Breast Cancer
    TAC Versus TC for Adjuvant Breast Cancer
    South Texas Cancer Center-McAllen
    McAllen, Texas 78503
    Breast Cancer
    Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
    South Texas Cancer Center - McAllen
    McAllen, Texas 78503-1298
    Androgen-independent Prostate Cancer
    A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
    Location #31
    McAllen, Texas 78503
    Metastatic Breast Cancer
    Ixabepilone + Carboplatin Metastatic Breast Cancer
    Texas Oncology-McAllen South Second Street
    McAllen, Texas 78509
    Metastatic Breast Cancer
    Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
    US Oncology - Texas Oncology - McAllen
    McAllen, Texas 78503
    Chronic Lymphocytic Leukemia
    Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
    Texas Oncology-McAllen South Second
    McAllen, Texas 78503
    Chronic Myeloid Leukemia
    Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
    Texas Oncology - McAllen South Second Street
    McAllen, Texas 78503
    Breast Cancer
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    Texas Oncology-McAllen
    McAllen, Texas 78503
    Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer
    A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
    Texas Oncology - McAllen
    McAllen, Texas 78503
    ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
    Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
    S. Texas Cancer Center
    McAllen, Texas 78503
    Prostate Cancer, Hormone Refractory Prostate Cancer
    Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
    South Texas Cancer Center - McAllen
    McAllen, Texas 78503-1298
    Carcinoma, Non-Small-Cell Lung
    Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
    South Texas Cancer Center-McAllen
    McAllen, Texas 78503
    Colorectal Cancer Metastatic
    Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
    South Texas Cancer Center-McAllen
    McAllen, Texas 78503
    Metastatic Breast Cancer
    TroVax Renal Immunotherapy Survival Trial
    Urology Associates of South Texas
    McAllen, Texas 78503
    Clear Cell Renal Carcinoma
    Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer
    Urology Associates of South Texas
    McAllen, Texas 78503
    Bladder Cancer
    A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
    Urology Associates of South Texas
    McAllen, Texas 78503
    Androgen-insensitive Prostate Cancer
    Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
    Urology Associates of South Texas
    McAllen, Texas 78503
    Bladder Neoplasm, Intravesical Drug Administration, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium